23 May 2013
Keywords: Agenus, Braind cancer, Vaccine, Glioblastoma Multiforme, Ph II
Article | 22 April 2012
USA-based Agenus (Nasdaq: AGEN) says that a Phase II multicenter trial of its autologous heat shock protein-peptide vaccine (HSPPC-96; vitespen) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 April 2012
24 April 2012
© 2013 thepharmaletter.com